m6A methylation controls the insulin IGF1-AKT-PDX1 pathway and T2DM is exacerbated by targeting METTL3 or METTL14 to reduce m6A levels and decrease AKT phosphorylation and PDX1 protein levels (De Jesus et al., 2019). Here, AKT1 is linked to type 2 diabetes mellitus.